Blog

PharmaTher Holdings Ltd.( OTCQB: PHRRF | CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, today released business highlights and audited financial results for its fiscal year ended May 31, 2022. All amounts in this press release are in Canadian dollars.  “We had achieved important clinical and business milestones that will pave the way for PharmaTher to potentially become a commercial-stage company in 2023. With a little over $12 million in cash and investment on our balance sheet, we are in a strong…

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc. (“Psilo Pharma”), from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner in Portugal (the “Research Partner”). In February 2022, Psyence received an import permit from the Portuguese regulators for the Research Partner in Portugal. It obtained the necessary, stringent permissions to commence with the export process and the psilocybin mushrooms were successfully delivered to the Research Partner’s facilities. Psilo Pharma will be using the mushrooms to develop extraction methodologies….

Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3Q | OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules. These capsules were produced according to defined manufacturing processes and product specifications as outlined in chemistry, manufacturing and controls (CMC) published guidelines. “NOVA has accomplished a major breakthrough in its autism spectrum disorder (ASD) clinical research program with the production of GMP grade psilocybin microdose capsules. NOVA is also excited to initiate the availability of the 1.5 mg…

Biomind Labs Inc. (NEO: BMND | OTC: BMNDF | FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the receipt of a Controlled Substances License and the commencement of an eight-month project to produce and evaluate novel rapidly-dissolving and sustained-release hydrogel-forming microneedle arrays designed for the transdermal delivery of Biomind’s key psychedelic compounds: N, N-dimethyltryptamine (‘DMT’), 5-methoxyN,N-dimethyltryptamine (‘5-MeO-DMT’) and mescaline. ‘As we continue expanding our operations in the United Kingdom, partnering with Queen’s University of Belfast, a…

Reunion Neuroscience Inc. (TSX: REUN | NASDAQ: REUN), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, announced the appointment of Greg Mayes as President and Chief Executive Officer. As Reunion’s new President and CEO, Mr. Mayes’ initial focus will be on the successful completion of the Company’s Phase 1 clinical trial with its lead asset, RE-104, a novel serotonergic psychedelic, which commenced in August 2022, and the planned launch of its Phase 2 study in postpartum depression, which is expected to commence in 2023. Mr. Mayes will also drive and accelerate…